“…We find VAS score was slightly lower in the LESS group at postoperative 24 hours for the salpingectomy, and this difference has statistical significance. Sangnier et al's [16] retrospective study involving 87 patients who underwent adnexal surgery indicated that there was no difference in pain scores at 2 or 24 hours after surgery. Jeong Eom's prospective case-control study which included 399 women indicated that the pain score was significantly lower in the LESS group compared with the conventional laparoscopic surgery group only at 2 hours after surgery, but no differences in VAS score at 48 and 72 hours after surgery [17].…”
Objective. To demonstrate various benign gynecologic diseases that can be performed by laparoendoscopic single-site surgery (LESS) with conventional laparoscopic instruments. Method. Patients with benign gynecologic diseases that need ovarian cystectomy, fallopian tube resection, or myomectomy were divided into experimental group and control group, and perioperative outcomes of these patients were analyzed. Results. From November 2017 to May 2018, 65 LESS gynecological surgeries were performed, among which there were 25 ovarian cystectomies, 28 unilateral fallopian tube resections, and 12 myomectomies. All the surgeries were completed smoothly, and only one surgery needed one more additional port. No patients have severe complications. Operative time, intraoperative blood loss, and perioperative complications have no difference between the two groups. The LESS laparoscopy group had less postoperative pain scores and longer bowel recovering time, compared with the conventional laparoscopy group (<0.05). Conclusion. Compared with traditional laparoscopy, LESS surgery with conventional laparoscopic instruments is feasible and safe, but postoperative exhaust time is longer than the control group.
“…We find VAS score was slightly lower in the LESS group at postoperative 24 hours for the salpingectomy, and this difference has statistical significance. Sangnier et al's [16] retrospective study involving 87 patients who underwent adnexal surgery indicated that there was no difference in pain scores at 2 or 24 hours after surgery. Jeong Eom's prospective case-control study which included 399 women indicated that the pain score was significantly lower in the LESS group compared with the conventional laparoscopic surgery group only at 2 hours after surgery, but no differences in VAS score at 48 and 72 hours after surgery [17].…”
Objective. To demonstrate various benign gynecologic diseases that can be performed by laparoendoscopic single-site surgery (LESS) with conventional laparoscopic instruments. Method. Patients with benign gynecologic diseases that need ovarian cystectomy, fallopian tube resection, or myomectomy were divided into experimental group and control group, and perioperative outcomes of these patients were analyzed. Results. From November 2017 to May 2018, 65 LESS gynecological surgeries were performed, among which there were 25 ovarian cystectomies, 28 unilateral fallopian tube resections, and 12 myomectomies. All the surgeries were completed smoothly, and only one surgery needed one more additional port. No patients have severe complications. Operative time, intraoperative blood loss, and perioperative complications have no difference between the two groups. The LESS laparoscopy group had less postoperative pain scores and longer bowel recovering time, compared with the conventional laparoscopy group (<0.05). Conclusion. Compared with traditional laparoscopy, LESS surgery with conventional laparoscopic instruments is feasible and safe, but postoperative exhaust time is longer than the control group.
“…LESS is widely used in various surgical disciplines [10][11][12], and some studies have shown that LESS has the advantages of alleviating postoperative pain, shortening average hospital stays and better cosmetic effect compared with traditional laparoscopy [13,14]. However, some studies suggested that traditional LESS has no obvious advantages compared with traditional laparoscopy [6,7]. The study of Sangnier et al believed that there was no significant difference between LESS and traditional laparoscopy in terms of postoperative pain, but experienced operators can shorten the operation time by LESS [6].…”
Section: Discussionmentioning
confidence: 99%
“…However, some studies suggested that traditional LESS has no obvious advantages compared with traditional laparoscopy [6,7]. The study of Sangnier et al believed that there was no significant difference between LESS and traditional laparoscopy in terms of postoperative pain, but experienced operators can shorten the operation time by LESS [6]. Reviewing the development of laparoscopic surgery, it can be seen that the direction and goal of the continuous development of LESS is to ensure or even make the minimally invasive advantages of laparoscopic surgery more obvious while enlarging surgical indications and completing more difficult and complex operations.…”
Section: Discussionmentioning
confidence: 99%
“…The feasibility of LESS have been confirmed by a large number of studies, Robotic LESS and vaginal natural orifice transluminal endoscopic surgery (vNOTES) [1][2][3][4][5]. However, there are also some scholars who believe that LESS has no obvious advantages over traditional porous laparoscopy [6,7]. In addition, with the improvement of living standards, the majority of women have higher and higher requirements for scarless treatment.…”
Objective: To investigate the feasibility of 5mm mini-•incision Laparoendoscopic Single-Site hysterectomy and Laparoendoscopic Single-Site hysterectomy in terms of safety, postoperative pain and cosmetic effect. Methods: The medical records of 19 patients who underwent hysterectomy with 5mm mini-•incision Laparoendoscopic Single-Site Surgery (LESS) or traditional Laparoendoscopic Single-Site Sugery in the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University from December 2017 to June 2020 were retrospectively analyzed, including 6 cases in the group of 5mm mini-•incision Laparoendoscopic Single-Site hysterectomy through umbilical ordinary incision (5mm) and 13 cases in the group of traditional Laparoendoscopic Single-Site hysterectomy through umbilical ordinary incision (1.5cm-3cm). Collect and compare the intraoperative blood loss, the operative time, the postoperative hemoglobin descender, the postoperative hospital stays, the probability of postoperative wound infection, the total cost, Visual analogue scale (VAS) of 12 hours after surgery, VAS of 24 hours after surgery and postoperative Body Image Questionnaire (BIQ, including Body Image scale, BIS and Cosmetic Score, CS) in the two groups. Results: There was no intraoperative complication happened, and there was no significant difference between the two groups in the forms of the intraoperative blood loss, operative time, postoperative hospital stays, postoperative hemoglobin descender, the probability of postoperative wound infection, the total cost, VAS of 24 hours after surgery and CS (P > 0.05). But the VAS of 12 hours after surgery of the 5mm mini-•incision Laparoendoscopic Single-Site hysterectomy was lower than traditional Laparoendoscopic Single-Site hysterectomy (1.17±0.14 vs. 2.33±0.19), the BIS of the former was higher than the later (19.83±0.15 vs 19.16±0.28), and importantly the difference was statistically significant (P < 0.05). Conclusion: Laparoendoscopic Single-Site through 5mm mini-incision is safe and feasible. Compared with traditional Laparoendoscopic Single-Site Hysterectomy through ordinary incision, it can not only significantly reduce postoperative pain, but also bring more satisfactory postoperative cosmetic effect.
“…Surgical techniques in the field of gynecologic surgery have shifted from the conventional open transabdominal approach to LESS, where laparoendoscopic procedures are performed through a single umbilical incision. LESS has been shown to yield numerous benefits, such as decreased postoperative pain, shorter hospital stay, and faster recovery to normal daily activities [14][15][16][17][18][19]. As the incision is created in the umbilicus, the surgical scar is concealed, providing aesthetic superiority.…”
Objective To investigate the role of port-site bupivacaine hydrochloride injection in laparoendoscopic single-site surgery (LESS) as a means of postoperative umbilical pain alleviation. Methods A total of 200 consecutive patients who underwent LESS from October 2018 to February 2019 were included in this randomized prospective case control study. The patients were alternatively assigned to either the study group (0.25% 10-mL bupivacaine hydrochloride injection at the 1.5-cm umbilical incision site after surgery) or the control group (no injection). All patients underwent surgery at the National Health Insurance Service Ilsan Hospital under the same operational setting by 3 board-certified gynecologists. Postoperative umbilical pain scores assessed using the visual analog scale were compared between the 2 groups as the primary outcome. Student's t-test, χ 2 test, and a linear mixed model were used for the statistical analysis. A P-value of <0.05 was considered to be statistically significant. Results The patients' age, body mass index, and menopausal status; type of surgery performed; and need for additional trocar insertion exhibited a significant difference between the bupivacaine injection and non-injection groups. After adjusting for various confounding variables, the postoperative umbilical pain scores measured at postoperative 2-3 hours, 6-10 hours, 1 day, and 3 days did not exhibit a significant difference between the 2 groups. Conclusion Port-site bupivacaine injection in LESS did not show any additive effect in alleviation of postoperative umbilical pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.